Skip to content

Additional Insulin for Fat and Protein in Children With Diabetes Study

Investigation of Appropriate Timing of Additional Insulin Dosing for Fat and Protein in Children With Type 1 Diabetes Using Multiple Daily Injections

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02680054
Enrollment
38
Registered
2016-02-11
Start date
2016-02-29
Completion date
2018-08-31
Last updated
2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Brief summary

The aims of the study are to see if additional insulin doses for the fat and protein in a meal, given at different times, improve blood glucose levels and are safe and acceptable to children with Type 1 diabetes using multiple daily insulin injections.

Detailed description

The study design is a repeated measures study involving the provision of a standard high protein/high fat evening test meal on 3 different evenings within a 7-day period in the same study subject. The children/adolescents will be instructed to give an insulin dose for the carbohydrate before the meal (calculated using their optimal insulin to carbohydrate (ICR) - 20%). In addition they will have an additional dose for the fat and protein content either before (together with the dose for the carbohydrate in the meal \[control meal\]), 1 hour after, or 2 hours after the meal. These will be carried out in a random order in each subject. Continuous glucose monitoring (CGM) will be carried out for the whole 7 day period. Questionnaires will assess the acceptability to young people and their parents of the extra insulin doses. After an initial contact in the clinic, and provision of patient information leaflets, the research nurse or dietitian will telephone the patient and family after a week to answer any questions they may have about the study. If they are keen to participate, an appointment will be arranged for consent and to commence the study (Visit 1). At Visit 1 the investigators will obtain informed consent and commence a week-long run-in period for participants to optimise insulin to carbohydrate ratio at the evening meal. During this week subjects will be requested to test capillary blood glucose (BG) levels at 7 points throughout the day (pre-meals, 2 hrs after meals and bed). They will be asked to eat a fat and protein free meal on one of these days. If necessary, adjustments to the insulin to carbohydrate ratio (ICR) or long-acting insulin doses will be made over the telephone by an experienced member of their clinical team. This is to decrease the likelihood of a correction bolus for a high BG level being required at the evening meal during the study week. At the end of the run-in week, participants will then attend the outpatient clinic or day care ward research facility at the Oxford Children's Hospital or the Horton Hospital outpatient clinic in Banbury or the Royal Berkshire Hospital in Reading (Visit 2). At this visit, the subcutaneous glucose sensor will be inserted by the research nurse and children and young people and their families will be trained on its use prior to the study commencing. CGM records glucose levels every 5 minutes over 7 days and thus provides much more information than routine capillary BG testing. It also alarms to alert patients of high and low glucose levels. Children and young people will also record their BG levels from routine finger pricks, pre-prandially and before bed and on waking in the morning. Also at Visit 2, the study dietitian will review BG readings and food diary from the previous week and optimise ICR doses of rapid acting insulin. This ratio will then be used to calculate insulin doses for the study meals. On three evenings over the next 7 days, the children will eat a standard high protein/high fat meal. The evenings will not be set, but will depend on the child and family schedule. The child and family will be able to choose which days during the study period on which they complete the study meals but will be advised to avoid days when the participant has undertaken lots of exercise, has had frequent hypoglycaemic episodes or has been unwell. The standard meal will be a portion controlled gluten-free meal provided and delivered by Wiltshire Farm Foods consisting of a meat-based main course and dessert. These will be kept frozen until used by participants and prepared according to manufacturer instructions. These meals come in two sizes which allow portion sizes to be adjusted for different ages of child, but the proportions of fat, protein and carbohydrate will be kept constant for each child, and by definition the meals will be high in protein and high in fat. Insulin doses with the standard meal will be given according to calculations carried out by the dietitian and administered in one of three ways. The three evenings in random order will be as follows: 1. Insulin units based on ICR minus 20%, and fat/protein dose given together immediately before the meal \[control meal\]. 2. Insulin units based on ICR minus 20%, given immediately before the meal plus extra insulin for fat/protein units given 1 hour after the meal. 3. Insulin units based on ICR minus 20% given immediately before the meal plus extra insulin for fat/protein units given 2 hours after the meal. Full written instructions will be provided to the family for all aspects of the insulin dosing for the study meals. During the study on the standardised meal days children will be instructed not to eat any food after the meal during the evening, and not to correct any later BG levels unless they are dangerously high (BG over 16 mmol/l with ketones over 0.5 mmol/l). If BG levels go low at any time (BG less than 4 mmol/l) children will be instructed to treat the hypoglycaemia according to their usual management. This data will be analysed separately. Children and families will be asked to complete diaries during the trial week. At the end of the study period (the day after the third meal), children will come back to the research facility or clinic for the end of study visit (visit 3). A research nurse or dietitian will remove the CGM sensor and download the data onto a secure laptop. Children and their families will then be asked to complete a short questionnaire about the acceptability of using the extra insulin doses, and their perceptions as to whether there were any beneficial or adverse effects. The study dietitian will calculate standard outcomes from each patient's sensor download and pass on anonymously to the study statistician to analyse the data.

Interventions

This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal

Sponsors

Oxford University Hospitals NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Type 1 diabetes (for at least a year) * On multiple daily insulin injections, including basal long-acting insulin and rapid-acting insulin before each meal. * HbA1c \< 75 mmol/mol (9.0%) * Participant and/or parent/legal guardian willing and able to give informed consent for participation in the study. * Family have a freezer in which to safely store the test meals. * In the Investigator's opinion, is able and willing to comply with all trial requirements.

Exclusion criteria

* HbA1c greater than 75 mmol/mol (9.0%) * Child unwilling to agree to second insulin injection at a meal-time * Untreated coeliac disease or other concomitant condition likely to affect BG control * Food allergies (other than controlled Coeliac Disease) * Vegetarians, vegans or patients with religious dietary restrictions (as the standard meal contains meat) * Participant taking any glucose-containing medication concurrently

Design outcomes

Primary

MeasureTime frameDescription
Peak Glucose Level Following Test Mealassessed up to 12 hours following the test mealGlucose measured on the continuous subcutaneous glucose monitor
Peak Glucose Excursion From Baseline Following Test Mealassessed up to 12 hours following the test mealGlucose measured on the continuous subcutaneous glucose monitor
Time of Peak Glucose Level Following Test Mealassessed up to 12 hours following the test mealGlucose measured on the continuous subcutaneous glucose monitor

Secondary

MeasureTime frameDescription
Number of Participants With Hypoglycaemia Events Following the Insulin Dosingassessed up to 12 hours following the test mealAll episodes of hypoglycaemia (BG less than 4 mmol/l) either on continuous glucose monitor or self-monitoring of BG

Other

MeasureTime frameDescription
Acceptability of Giving Insulin at Different Times Related to Test Mealquestionnaires completed up to a week after the test mealsWould young people continue to give extra insulin injections for High Fat High Protein (HFHP) meals

Countries

United Kingdom

Participant flow

Pre-assignment details

Study was closed before target could be reached due to exhaustion of eligible participants

Participants by arm

ArmCount
All Study Participants
Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal, then +1hr, then +2hr. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child. Insulin, Asp(B28)-: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
27
Total27

Baseline characteristics

CharacteristicAll Study Participants
Age, Categorical
<=18 years
27 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Duration of T1 Diabetes3.5 years
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United Kingdom
27 Participants
Sex: Female, Male
Female
12 Participants
Sex: Female, Male
Male
15 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 270 / 270 / 27
other
Total, other adverse events
0 / 270 / 270 / 27
serious
Total, serious adverse events
0 / 270 / 270 / 27

Outcome results

Primary

Peak Glucose Excursion From Baseline Following Test Meal

Glucose measured on the continuous subcutaneous glucose monitor

Time frame: assessed up to 12 hours following the test meal

ArmMeasureValue (MEAN)Dispersion
Arm 1 (Usual Treatment)Peak Glucose Excursion From Baseline Following Test Meal1.864 mmol/lStandard Deviation 0.716
Arm 2Peak Glucose Excursion From Baseline Following Test Meal1.167 mmol/lStandard Deviation 0.72
Arm 3Peak Glucose Excursion From Baseline Following Test Meal2.459 mmol/lStandard Deviation 0.712
Primary

Peak Glucose Level Following Test Meal

Glucose measured on the continuous subcutaneous glucose monitor

Time frame: assessed up to 12 hours following the test meal

ArmMeasureValue (MEAN)Dispersion
Arm 1 (Usual Treatment)Peak Glucose Level Following Test Meal10.931 mmol/lStandard Deviation 0.951
Arm 2Peak Glucose Level Following Test Meal11.491 mmol/lStandard Deviation 0.831
Arm 3Peak Glucose Level Following Test Meal11.491 mmol/lStandard Deviation 0.863
Primary

Time of Peak Glucose Level Following Test Meal

Glucose measured on the continuous subcutaneous glucose monitor

Time frame: assessed up to 12 hours following the test meal

ArmMeasureValue (MEAN)Dispersion
Arm 1 (Usual Treatment)Time of Peak Glucose Level Following Test Meal82.34 MinsStandard Deviation 35.37
Arm 2Time of Peak Glucose Level Following Test Meal113.617 MinsStandard Deviation 30.922
Arm 3Time of Peak Glucose Level Following Test Meal95.106 MinsStandard Deviation 32.092
Secondary

Number of Participants With Hypoglycaemia Events Following the Insulin Dosing

All episodes of hypoglycaemia (BG less than 4 mmol/l) either on continuous glucose monitor or self-monitoring of BG

Time frame: assessed up to 12 hours following the test meal

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Arm 1 (Usual Treatment)Number of Participants With Hypoglycaemia Events Following the Insulin Dosing14 Participants
Arm 2Number of Participants With Hypoglycaemia Events Following the Insulin Dosing14 Participants
Arm 3Number of Participants With Hypoglycaemia Events Following the Insulin Dosing16 Participants
Other Pre-specified

Acceptability of Giving Insulin at Different Times Related to Test Meal

Would young people continue to give extra insulin injections for High Fat High Protein (HFHP) meals

Time frame: questionnaires completed up to a week after the test meals

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Arm 1 (Usual Treatment)Acceptability of Giving Insulin at Different Times Related to Test Meal11 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026